Copertina

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yanyan Liu, Ningjing Lin, Shuhua Yi, Huiqiang Huang, Ye Guo, Qingyuan Zhang, Haiyan Yang, Huilai Zhang, Liling Zhang, Ru Feng, Yijiao Qian, Jiankun Zhu, Yuqin Song, Jun Zhu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	International Journal of Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment‐naive peripheral T‐cell lymphoma: A multicenter, open‐label, single‐arm, phase 1b trial
di: Yan Gao, et al.
Pubblicazione: (2026)

A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02)
di: Yushi Hirota, et al.
Pubblicazione: (2024)

Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial
di: Michio Ozeki, et al.
Pubblicazione: (2025)

Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
di: Yuqin Song, et al.
Pubblicazione: (2025)

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
di: Hannah Goulart, et al.
Pubblicazione: (2025)

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL‐BRB trial
di: Giulia Benevolo, et al.
Pubblicazione: (2024)

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
di: Prashant Kapoor, et al.
Pubblicazione: (2024)

Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study
di: Haiyan Ma, et al.
Pubblicazione: (2025)

A multicenter, single‐arm, open‐label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder
di: Kazuyuki Nakagome, et al.
Pubblicazione: (2024)

A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
di: Hongtao Duan, et al.
Pubblicazione: (2024)

Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
di: Yuzhou Zhao, et al.
Pubblicazione: (2024)

Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial
di: Emanuela Palmerini, et al.
Pubblicazione: (2024)

Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study
di: Peng Zhao, et al.
Pubblicazione: (2024)

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study
di: Guang‐Liang Chen, et al.
Pubblicazione: (2024)

Efficacy and safety of a digital therapeutic for alcohol dependence: A multicenter, open‐label, randomized controlled trial
di: Ryuhei So, et al.
Pubblicazione: (2025)

A study protocol for an open‐label, single‐arm, single‐center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma
di: Huiying Huang, et al.
Pubblicazione: (2024)

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003)
di: Paolo Strati, et al.
Pubblicazione: (2024)

Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP): A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial
di: Asieb Sekandarzad, et al.
Pubblicazione: (2024)

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial
di: Congqing Pan, et al.
Pubblicazione: (2025)

A prospective, randomized, multicenter, open‐label trial comparing survival in subjects receiving peritoneal dialysis or conventional in‐center hemodialysis
di: Li Fan, et al.
Pubblicazione: (2024)

Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
di: Yu‐Han Gao, et al.
Pubblicazione: (2024)

Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
di: Jianli Zhao, et al.
Pubblicazione: (2024)

Electroencephalography‐based investigation of the effects of oral desmopressin on improving slow‐wave sleep time in nocturnal polyuria patients (the DISTINCT study): A single‐arm, open‐label, single‐assignment trial
di: Kazumasa Torimoto, et al.
Pubblicazione: (2024)

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open‐label, phase I/II study
di: Ivetta Danylesko, et al.
Pubblicazione: (2025)

Causal Network Discovery from Interventional Count Data with Latent Linear DAGs
di: Zhang, Yijiao, et al.
Pubblicazione: (2026)

Transfer Learning for High-dimensional Quantile Regression with Distribution Shift
di: Bai, Ruiqi, et al.
Pubblicazione: (2024)

Direct Multi‐Deuterium Labelling of Pirtobrutinib
di: Michal Kriegelstein, et al.
Pubblicazione: (2024)

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial
di: Albertas Ulys, et al.
Pubblicazione: (2024)

Impact of core thickness and opening height on the combustion characteristics of polyethylene sandwich panels
di: Peng Wu, et al.
Pubblicazione: (2024)

CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives
di: Rui Zhang, et al.
Pubblicazione: (2025)

Efficacy of probiotics ( Bifidobacterium bifidum G9 ‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study ( BIRDIE study)
di: Fuki Ikeda, et al.
Pubblicazione: (2026)

A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis
di: Jian Yin, et al.
Pubblicazione: (2024)

Covariate-Elaborated Robust Partial Information Transfer with Conditional Spike-and-Slab Prior
di: Zhang, Ruqian, et al.
Pubblicazione: (2024)

Individualized Dynamic Mediation Analysis Using Latent Factor Models
di: Zhang, Yijiao, et al.
Pubblicazione: (2024)

Syntax-Guided Diffusion Language Models with User-Integrated Personalization
di: Zhang, Ruqian, et al.
Pubblicazione: (2025)

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults
di: Sven C. van Dijkman, et al.
Pubblicazione: (2026)

Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial
di: Ling‐Long Tang, et al.
Pubblicazione: (2025)

Feasibility, safety, and clinical outcomes of modified laparoscopic cervicoisthmic cerclage for refractory cervical insufficiency: A single‐arm clinical trial—Part 1
di: Kohei Seo, et al.
Pubblicazione: (2024)

Bayesian Environment Invariant Regression
di: Zhang, Ruqian, et al.
Pubblicazione: (2026)

Efficacy of adalimumab combined with Tripterygium wilfordii Hook F in the treatment of patient with rheumatoid arthritis: A multicenter, open‐label, randomized‐controlled trial
di: Feng Luo, et al.
Pubblicazione: (2024)